Anterior (front) temporal lobe removal for temporal glioblastoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

ATLAS/NOA-29 is a prospective, multicenter, randomized phase III trial comparing a standardized anterior temporal lobectomy (ATL) technique adapted from epilepsy surgery with conventional gross-total resection (GTR) for newly diagnosed glioblastoma confined to the anterior temporal lobe. Patients are randomized intraoperatively 1:1 after frozen-section confirmation of a diffuse high-grade glioma, and surgery follows predefined anatomical boundaries for supramarginal resection. The primary endpoint is overall survival, with a co-objective to confirm non-inferiority for health-related quality of life using validated instruments. Eligibility is limited to tumors within defined distances from the temporal pole (up to 6.5 cm non-dominant, 4.0 cm dominant) and where macroscopic complete resection is judged achievable by the neurosurgeon.

Why it matters

Who can join: the full rules

* Suspected glioblastoma with contrast-enhancement in preoperative MRI
* Diffuse high-grade glioma in frozen section procedure, newly-diagnosed
* Tumor localization (in gadolinium-enhanced MRI): solely temporal, non-dominant side (right hemisphere in right-handed patients, or left-handed patients after testing for dominance): within 6.5 cm from the temporal pole; dominant side (left hemisphere in right-handed patients, all left-handed patients unless additional testing for dominance performed): within 4.0 cm from the temporal pole, as determined dorsally along the Sylvian fissure.
* Macroscopic complete resection (no remaining contrast-enhancing tumoral lesion on early postoperative MRI) is achievable (decision of the treating neurosurgeon)
* In case further T1-contrast-enhancing and/or T2/FLAIR lesions are detected beyond the resection margins (6.5 cm on the non-dominant side and 4.0 cm on the dominant side), these lesions are not attributed to the tumor (except perifocal edema) but to other conditions according to the local treating neurosurgeon
* ≥ 18 and \< 75 years of age
* KPS ≥ 70%
* Estimated life expectancy of at least 6 months
* Written informed consent
* Cognitive state to understand the rationale and necessity of the study therapy and procedures
* Patient compliance and geographic proximity that allow adequate follow-up
* For patients with childbearing potential: negative serum pregnancy test (beta-HCG) at baseline visit, patient's commitment to use an approved contraceptive method during the trial and for 3 months after (Pearl index \< 1%)
* Adequate organ function at baseline visit that does not preclude alkylating chemotherapy and neurosurgical procedures (all criteria required):

  * Adequate bone marrow reserve: white blood cell (WBC) count ≥ 3.000/µl; granulocyte count \> 1.500/µl; platelets ≥ 100.000/µl; haemoglobin ≥ 10 g/dl
  * Adequate liver function: bilirubin \< 1.5 times above upper limit of normal range (ULN); alanine transaminase (ALT/SGPT) and aspartate transaminase (AST/ALAT) \< 3 times ULN
  * Adequate renal function: creatinine \< 1.5 times ULN
* Adequate blood clotting: Partial Thromboplastin Time (PTT) not exceeding the upper limit of normal range and International Normalized Ratio (INR) \<1.5; in case of intake of anticoagulant medication or platelet function inhibitors, the coagulation analysis must show no detectable effect in specific blood tests (as described below) at the time of surgery, and discontinuation of the anticoagulant medication must be justifiable for at least 1 week postoperatively

  * Direct acting oral anticoagulants (e.g., rivaroxaban, apixaban, edoxaban, dabigatran): anti-Factor Xa (aFXa)-activity within the normal range (rivaroxaban, apixaban, edoxaban), TT/TCT (thrombin clotting time) or ecarin clotting time (ECT) not exceeding the upper limit of normal range (Dabigatran) or verification of subtherapeutic drug levels (apixaban, edoxaban, rivaroxaban, dabigatran)
  * Vitamin K antagonists (coumarins): INR \< 1.5
  * Unfractionated heparin (UFH) and argatroban: activated Partial Thromboplastin Time (aPTT) not exceeding the upper limit of normal range
  * Fractionated heparin/low-molecular-weight heparin (e.g., dalteparin, enoxaparin), heparinoid (e.g., fondaparinux, danaparoid): aFXa-activity within the normal range
  * Antiplatelet agents (aspirin, clopidogrel, prasugrel, ticagrelor): platelet function analyzer (PFA) test not exceeding the upper limit of normal range (aspirin), whole blood aggregometry not below lower limits of normal range (clopidogrel, prasugrel, ticagrelor)

For details see study protocol.

Where it's running

• University Hospital Bonn
  Bonn, North Rhine-Westphalia, Germany Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Maintenance radiotherapy after standard glioblastoma treatment

  This study tests whether a single 2 Gy maintenance radiotherapy dose after standard treatment is safe and feasible for adults with newly diagnosed glioblastoma.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT07831772

• AAV dual-payload gene therapy injected directly into high-grade glioma to kill tumor cells and stimulate immune attack.

  This will try TGX-007, a virus-delivered gene therapy given into the tumor together with oral valaciclovir, in adults 18–70 with newly diagnosed or recurrent glioblastoma to see if it safely kills tumor cells and boosts immune response.

  Recruiting at 2 sites Phase 1/2 Trogenix ltd · Columbus, Ohio and 1 other locations · NCT07346144

• Silevertinib plus temozolomide for newly diagnosed GBM with unmethylated MGMT and EGFRvIII

  This trial tests whether adding silevertinib to standard temozolomide helps people with newly diagnosed glioblastoma that have EGFRvIII and an unmethylated MGMT promoter live longer without the cancer getting worse.

  Recruiting at 38 sites Phase 2 Black Diamond Therapeutics, Inc. · Birmingham, Alabama and 37 other locations · NCT07326566

• Nivolumab with or without relatlimab for newly diagnosed IDH‑wildtype glioblastoma

  This trial will test whether giving nivolumab alone or together with relatlimab around surgery helps adults with newly diagnosed IDH‑wildtype glioblastoma.

  Recruiting at 4 sites Phase 2 Duke University · New York, New York and 3 other locations · NCT06816927

• New cancer vaccine for glioblastoma patients

  This study is testing a new cancer vaccine for people with newly diagnosed glioblastoma to see if it can help boost their immune response after standard treatment.

  Recruiting at 2 sites Phase 1/2 Assistance Publique - Hôpitaux de Paris · Paris, Idf and 2 other locations · NCT06622434

• Personalized drug screening for glioblastoma treatment

  This study is testing if personalized combinations of FDA-approved drugs can improve treatment for people with newly diagnosed glioblastoma when used with standard therapy.

  Recruiting Early Phase 1 Swedish Medical Center · Seattle, Washington · NCT05380349

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.